Rua Bioscience Signs Its Largest Export Deal With UK Clinic

Rua Bioscience, a small New Zealand-listed medicinal cannabis producer, has signed the biggest export agreement in its history: a sales and distribution deal with an unnamed British cannabis clinic that the company expects to bring in more than NZ$10 million over its initial two-year term.

For a firm that reported NZ$1.33 million in revenue across its most recent half-year, that is not a routine sales update. The projected figure works out to roughly NZ$5 million a year, close to double what the entire company currently sells across all of its markets combined.

Under the agreement, Rua will supply medical cannabis flower grown in New Zealand to one of the larger clinic and distribution operators in the UK’s private medical cannabis market. The partner asked not to be named while it runs its own announcement process, but the structure is what matters commercially. The deal hands Rua immediate access to an established network of clinics, pharmacies and prescribers, the kind of route to market the company says would otherwise take years to build on its own.

It is also a clear step up from Rua’s existing UK position. The company has sold a small range of cannabis oils in Britain since 2023 through distributor Target Healthcare, and had recently told shareholders it was reworking that arrangement to push its own genetics through new clinic chains. Flower typically moves in larger volumes and at higher value than oils, so the new deal is the payoff from that review: a move from a modest oils listing to a supply contract with a major buyer.

Why the deal size matters

Rua runs a deliberately capital-light model. It outsources cultivation and manufacturing and concentrates on plant genetics, branding and distribution. That keeps fixed costs low, but it also means growth depends almost entirely on winning supply agreements in higher-value export markets rather than on building out its own production base.

Its most recent half-year results, for the six months to December 31, 2025, show why a single contract can move the needle. Revenue from customers rose 92% year on year to NZ$1.33 million, yet the company still ran a loss before tax of NZ$1.79 million and burned through NZ$1.52 million in operating cash. It also leaned on shareholders during the period, raising about NZ$2.3 million through a rights offer and share placement to fund its expansion.

Against numbers like those, a deal projected to deliver more than NZ$10 million over two years is genuinely material. The company has yet to reach profitability, which makes a contract of this scale central to its path toward it. The usual caution applies: the figure is Rua’s own forecast for a supply-and-distribution arrangement, not booked revenue, and the company has not disclosed pricing, volumes or the buyer’s identity. Rua placed its shares in a trading halt on July 8, 2026 ahead of the disclosure, an indication of how material it judged the news to be.

A crowded, import-hungry market

Britain has become one of the most sought-after destinations for cannabis exporters. Rua cited data putting the UK market at an estimated £226 million in 2025, more than double the prior year, with imports reaching about 30 tonnes, nearly three times 2022 levels. The market is almost entirely supplied from overseas, and Canadian producers have so far dominated that import trade. Between 90,000 and 94,000 patients now access medical cannabis through private clinics, against an eligible population the UK’s health department estimates at up to three million.

That gap between who is treated today and who could be is the commercial draw, and it has pulled in a steady stream of overseas suppliers and clinic operators. Prescribing is also unusually concentrated: in England, a small group of clinics and pharmacist prescribers now write the bulk of private cannabis scripts, which makes a distribution partner with existing prescriber relationships especially valuable to a newcomer. Rivals have taken similar routes in, including Curaleaf, which has routed Portuguese-grown flower into the UK through partnerships.

Rua’s pitch is differentiation. It is selling New Zealand-grown flower developed from genetics sourced in the country’s legacy market, which it argues stands out in a field crowded with Canadian and European product. “Our strategy has always been to connect Rua’s differentiated New Zealand genetics with high-value international markets,” chief executive Paul Naske said, describing the deal as validation of the company’s New Zealand-grown offering.

What to watch next

The UK contract adds to a commercial footprint that Rua says already spans five other markets: Germany, Australia, Canada, the Czech Republic and New Zealand. It has taken its genetics into Canada through a royalty arrangement with Apollo Green and distributes across parts of central and eastern Europe through its Czech partner Motagon. The open question is execution: whether flower shipments into the UK actually convert into the revenue Rua is forecasting, and whether the still-unnamed clinic proves as large as described. For a company that has spent years building supply lines faster than sales, this is the contract that has to turn strategy into cash.